bmiMD

bmiMD sells physician-formulated GLP-1 weight-management protocols, compounded tirzepatide and semaglutide injections, plus supporting supplements (B-complex, magnesium, probiotics). All medication is shipped frozen from U.S. pharmacies; plans start around $299 for a 4-week starter dose and rise to $599 for the highest maintenance strength. The brand is online-only: patients complete a telehealth intake, upload labs, and receive doorstep delivery if prescribed. The company differentiates by bundling unlimited provider messaging, nutrition coaching, and dose-adjustment visits into the drug price—no separate app fees. Medication is compounded in small batches to order, letting bmiMD offer two vial strengths not found in standard starter pens and ship in temperature-stable cold packs that keep potency for 72 h. A 90-day outcomes guarantee—free month if weight loss is under 5 %—is heavily promoted on TikTok and Instagram. Core buyers are 28-55-year-old professionals (70 % female) with ≥25 BMI who want clinical-grade loss without sitting in a clinic. They value transparent pricing, on-demand texting with an NP, and the discretion of home delivery over branded injectables advertised on TV. Many report choosing bmiMD after insurance denied name-brand GLP-1 coverage. bmiMD competes with telehealth platforms, med-spas, and compounding pharmacies that market similar peptides. It undercuts cash-pay retail prices by 20-30 % while wrapping physician oversight, coaching, and cold-chain logistics into one subscription, positioning itself as the fastest route from online consult to doorstep medication without sacrificing medical supervision.